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Abstract 
Urine metabolomics has recently emerged as a prominent field for the discovery of non-invasive 
biomarkers that can detect subtle metabolic discrepancies in response to a specific disease or therapeutic 
intervention. Urine, compared to other biofluids, is characterized by its ease of collection, richness in 
metabolites and its ability to reflect imbalances of all biochemical pathways within the body. Following 
urine collection for metabolomic analysis, samples must be immediately frozen to quench any biogenic 
and/or non-biogenic chemical reactions. According to the aim of the experiment; sample preparation can 
vary from simple procedures such as filtration to more specific extraction protocols such as liquid-liquid 
extraction. Due to the lack of comprehensive studies on urine metabolome stability, higher storage 
temperatures (i.e. 4 °C) and repetitive freeze-thaw cycles should be avoided. To date, among all 
analytical techniques, mass spectrometry (MS) provides the best sensitivity, selectivity and 
identification capabilities to analyze the majority of the metabolite composition in the urine. Combined 
with the qualitative and quantitative capabilities of MS, and due to the continuous improvements in its 
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related technologies (i.e. ultra high-performance liquid chromatography [UPLC] and hydrophilic 
interaction liquid chromatography [HILIC]), liquid chromatography (LC)-MS is unequivocally the most 
utilized and the most informative analytical tool employed in urine metabolomics. Furthermore, 
differential isotope tagging techniques has provided a solution to ion suppression from urine matrix thus 
allowing for quantitative analysis. In addition to LC-MS, other MS-based technologies have been 
utilized in urine metabolomics. These include direct injection (infusion)-MS, capillary electrophoresis-
MS and gas chromatography-MS. In this article, the current progresses of different MS-based techniques 
in exploring the urine metabolome as well as the recent findings in providing potentially diagnostic 
urinary biomarkers are discussed. 
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1. INTRODUCTION  
The discovery, validation and quantification of new biomarkers or “biological markers” are 
essential cornerstones in the field of biomedical research. One such target for biomarker identification is 
metabolites. Metabolomics is the study of metabolic profiles in a biological system and it is the endpoint 
in the omics cascade that starts with activated genes (genome) along with gene transcripts 
(transcriptome) and proteins (proteome) (Dettmer, Aronov & Hammock, 2007; Dunn et al., 2011; Jain, 
2010; Roberts et al., 2012). Changes at the metabolite level are natural outcomes of the onset and 
prognosis of many diseases and such changes often appear in biological fluids before the appearance of 
clinical symptoms (Van, Veenstra & Issaq, 2011). For this reason, the discovery of new diagnostic and 
prognostic biomarkers whether based on genomics (Borovecki et al., 2005; Hu et al., 2007; Moore et al., 
2008), proteomics (Hu et al., 2007; Zhang et al., 2004) or metabolomics (Gowda et al., 2008; Zhang et 
al., 2012b) can enhance the understanding of human diseases and eventually improve the quality of life 
of patients. 
Currently, there are two main approaches by which metabolomic studies can be conducted, 
namely metabolic profiling and fingerprinting (Fig 1) (Dettmer, Aronov & Hammock, 2007). Metabolic 
profiling or the “targeted approach” aims at identifying and quantifying a preselected category of 
metabolites within a sample (Dettmer, Aronov & Hammock, 2007; Griffiths et al., 2010; Patti, Yanes & 
Siuzdak, 2012; Roberts et al., 2012; Theodoridis, Gika & Wilson, 2011). Selection criteria can be based 
on either a common chemical functional group such as amino or carboxylic acid functionalities, or 
specific biochemical pathways. This targeted analysis is usually driven by a proposed hypotheses or a 
biochemical question (Fig 1) (Dettmer, Aronov & Hammock, 2007; Dunn et al., 2011; Griffiths et al., 
2010; Patti, Yanes & Siuzdak, 2012; Theodoridis, Gika & Wilson, 2011). On the other hand, 
fingerprinting or the “untargeted or global approach” compares unquantified metabolic profiles 
between analogous samples in an attempt of tracking differences in response to some internal or external 
factors (e.g. a disease, toxin or environmental stimulus) (Dettmer, Aronov & Hammock, 2007). 
Metabolic profiling and fingerprinting are complementary and their integrative implementation in 
biomarker discovery reveals the true power of the metabolome in understanding complex biochemical 
pathways. In fact, as seen in Fig 1, biomarker discovery involves sequential steps of first determining 
differences in the metabolic profiles between samples and then selecting the key altered metabolites as 
potential biomarkers. Secondly, targeted metabolites are quantified and their differential expression is 
justified through the understanding of the underlying biochemical pathways. For instance, statins are the 
first line of treatment of cholesterol induced atherosclerotic-cardiovascular diseases and they are known 
to elevate hepatic enzymes (Kumar at al., 2010). Therefore, it is necessary to identify biomarkers that 
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can indicate the first appearance of adverse effects (i.e. safety biomarkers). In order to detect liver 
toxicity markers for atorvastatin, hyperlipidemic rats were treated with either 70 mg/kg or 250 mg/kg 
atorvastatin for 7 days. Urinary profiles of these two groups were statistically different than those of 
control and hyperlipidemic control groups. Subsequently, urinary amino acids and steroidal metabolites, 
which were altered by the drug induced-liver damage, were quantified in a targeted approach. Six 
metabolites were identified as potential safety biomarkers for atorvastatin-induced liver toxicity. With 
the exception of two metabolites, the connections between candidate biomarkers and liver damage were 
explained  (Kumar et al., 2010).  
Among the various bodily fluids, urine is an attractive option for metabolome biomarker 
discovery. It can be readily obtained in large quantities non-invasively with expected high participant 
compliance. In addition, it poses low risk of infection to researchers (Miller et al., 2004). Assuming 
normal renal function, the fluid is filtered leaving low cell contamination. Concentrations of metabolites 
in the urine are often higher than that of plasma, thus providing a richer matrix for analysis (Adamko, et 
al., 2007; Miller et al., 2004). The use of urine as a source for biomarker discovery will be the focus of 
this review.  
Metabolites contain diverse classes of low-molecular weight compounds (<1500 Da) such as; 
amino acids, lipids, organic acids and nucleotides (Dettmer, Aronov & Hammock, 2007; Wishart et al., 
2013). They are of heterogeneous physicochemical properties, and they exist in very wide concentration 
ranges (pmol-mmol) ( Dettmer, Aronov & Hammock, 2007; Dunn et al., 2011; Dunn & Ellis, 2005; 
Wishart et al., 2013). The Human Metabolome Database (HMDB) is being continuously updated to 
include all known metabolites; their biofunction, pathways, locations and normal and abnormal 
concentrations. They are chemically categorized into a hierarchical pattern of kingdoms, super classes, 
classes and sub classes (Wishart et al., 2013). Unfortunately, unlike genes or proteins, metabolites are 
not specific to a single metabolicpathway. In most cases, several biochemical reactions can contribute to 
the production of a single metabolite within the urine (Kumar et al., 2012). Thus, metabolomics has the 
advantage of seeing the cumulative effect of an altered state within the body either due to drugs, diseases 
or any other pathophysiological condition. For example, changes in the urinary metabolomic profile 
have been identified throughout the different stages of pregnancy (Trivedi & Iles, 2014b). Four 
metabolites drastically decreased at the end of first trimester, while, an increased expression of a number 
of metabolites was observed in the mid second trimester. Such study can serve as a platform for the 
indication of a healthy fetal-maternal metabolism to which other pathologies of pregnancy can be 
compared to (Trivedi & Iles, 2014b). On the other hand, in addition to the complex nature of metabolites 
within urine; genetic and environmental stimuli are also known to influence the normal metabolome 
profile (Johnson & Gonzalez, 2012). For instance, based on a 50-metabolite profiling strategy using 
urine, 60 participants were successfully differentiated based on their age and gender (Slupsky et al., 
2007). Another non-targeted metabolome study was able to identify some major alterations in the urine 
metabolic profiles following whole grain rye and wheat bread consumption (Bondia‐Pons et al., 2013).  
Based on current technologies and the diversity of the physicochemical properties of metabolites, 
a single separation or detection technique, which can simultaneously identify all metabolites within a 
urine sample, is not available (Dettmer, Aronov, Hammock, 2007; Scalbert et al., 2009). Therefore, 
different analytical approaches must be adopted according to the properties of metabolites being 
investigated and the specific goal of the experiment ( Dettmer, Aronov, Hammock, 2007; Lei, Huhman, 
& Sumner, 2011; Scalbert et al., 2009). Recent improvements in mass spectrometry (MS) have 
expanded the range of metabolites that can be analyzed in urine for either metabolite identification or 
quantification.  Indeed, MS-based techniques are currently the most prevalent tools employed in 
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metabolomics studies (Dunn, 2008; Dunn et al., 2011; Griffiths et al., 2010; Johnson & Gonzalez, 2012). 
In this paper, we explore the advancements in MS-based techniques in targeted and untargeted urine 
metabolomic analysis, while providing comparisons between currently available technologies. In 
addition, urine handling for biomarker analysis will be reviewed and special emphasis will be given to 
the current status and the success of urine as a matrix for biomarker discovery.  
II. HANDLING OF URINE SAMPLES FOR MS ANALYSIS  
Bacterial, biogenic enzymatic reactions and non-biogenic oxidation reactions of metabolites are 
reported to alter the metabolic profile of urine (Bernini et al., 2011; Boomsma et al., 1993; Boyland, 
Wallace & Williams, 1955; Fernández-Peralbo & Luque de Castro, 2012; Ito et al., 2002; Jung & 
Pergande, 1983; Sykes, 2007; Udert et al., 2003; Zeisel, DaCosta & Fox, 1985). Bacterial enzymes are 
known to be active towards several metabolites such as urea (Udert et al., 2003), choline (Zeisel, 
DaCosta & Fox, 1985) and creatinine (Ito et al., 2002). Biogenic enzymes, namely glucuronidase and 
sulphatase maintain their conjugate-hydrolytic activity in normal urine for a period up to 10 days after 
collection ( Boyland, Wallace & Williams, 1955). In addition to enzymatic degradations, some labile 
compounds like catecholamines are easily oxidized into their corresponding quinones when kept at 37 
ºC for 1-2 days or at 20 ºC for 4-8 days (Boomsma et al., 1993). Therefore, the main target of urine 
sample collection and preparation is to ideally maintain the metabolomic state of the original sample, 
and to halt chemical/enzymatic reactions in urine that might give a misleading metabolomic picture of 
analyzed samples (Boomsma et al., 1993; Dunn et al., 2011; Sykes, 2007; Vuckovic, 2012). The 
following sections describe the available sampling modes, proper sample clean-up procedures as well as 
appropriate conditions for storing urine samples until the time of analysis.  
A. Urine Sampling Time 
Urine samples can be collected randomly (Adamko et al., 2007; Saude et al., 2009; Saude et al., 2011; 
Wittke et al., 2003), at pre-set time intervals (Tyburski et al., 2009; Want et al., 2010), for up to 24 hrs 
(Holmes et al., 2008; Tyburski et al., 2009; Urpi-Sarda et al., 2009; Want et al., 2010) or for longer 
periods (e.g. pharmacokinetic studies) (Tyburski et al., 2009). Mid-stream random sampling can be done 
anytime of the day, and it does not correct for the diurnal variation of excretion of some metabolites 
(Fernández-Peralbo & Luque de Castro, 2012). On the contrary, timed sampling is used to monitor the 
exact excretion pattern of metabolites exhibiting a circadian rhythm. It could also monitor metabolites 
produced following special diet, xenobiotic consumption, or response to stimulation (e.g. injury) 
(Fernández-Peralbo & Luque de Castro, 2012). One drawback of the 24-hrs sample collection technique 
is that it cannot provide information regarding the diurnal variation of excretion or the timing of 
excretion in response to stimuli (Fernández-Peralbo & Luque de Castro, 2012). In contrast, despite being 
labor intensive, this sampling procedure eliminates the vast variation in urine profile observed at shorter 
times of collection. As such , it gives the most accurate quantification of clinically important metabolites 
(Pinto-Sietsma et al., 2000; Remer et al., 2005).  
Ultimately, the purpose of the experiment dictates the proper sampling mode. For instance, 
changes in the urine profile of mice following the exposure to different doses of sub lethal gamma-
radiation were evaluated. Sampling protocol involved the collection of urine at 4 hrs intervals after 
exposure for a period of 20 hrs. In addition, subsequent full 24 hrs urine samples were collected at 3, 5, 
7 and 9 days following exposure (Tyburski et al., 2009). Six purine and pyrimidine derivatives exhibited 
significantly altered excretion behavior and were suggested as possible biomarkers for sub lethal 
radiation exposure. Elevated metabolites exhibited a time dependent excretion rate, where peak 
concentrations were detected in urine at 8-12 hrs after exposure and baseline levels were restored by 36 
This is the peer reviewed version of: Khamis, M. M., Adamko, D. J. and El-Aneed, A. (2015), Mass Spec Rev., 
published in final form at https://doi.org/10.1002/mas.21455. 
 
5 
University of Saskatchewan Author Manuscript, available April 16, 2017.  
 
hrs following irradiation. On the other hand, in the work of Saude et al. (Saude et al., 2009; Saude et al., 
2011), urine samples were intentionally collected randomly without any dietary restriction. Statistical 
analysis of the obtained data revealed sufficiently altered urinary metabolic profiles that allowed the 
differentiation between healthy and asthma guinea pigs (Saude et al., 2009) and children (Saude et al., 
2011) with accuracy of more than 90%.  
B. Sample Preparation 
Normal urine is composed of 95% water, organic compounds, electrolytes and metabolites with 
lower protein content in comparison to more complex biological fluids such as serum or plasma 
(Fernández-Peralbo & Luque de Castro, 2012; Want et al., 2010). Therefore, in general, urine sample 
preparation is one of the simplest processes employed in bioanalysis and the complexity of this step 
usually differs according to the aim of the experiment (Dunn et al., 2011; Fernández-Peralbo & Luque 
de Castro, 2012). Sample preparation in non-targeted analysis aims at keeping the sample as intact as 
possible containing all unknown metabolites with various physicochemical properties (Dunn et al., 
2011; Fernández-Peralbo & Luque de Castro, 2012). The method employed should be non-selective, 
fast, simple and reproducible (Fernández-Peralbo & Luque de Castro, 2012). For these reasons, the 
simplest unselective sample-preparation procedure is sample dilution or ultrafiltration (Vuckovic, 2012). 
“Dilute and Shoot” is a strategy for the preparation of simple biological matrices as urine. In this 
approach, the samples are only diluted with the appropriate solvents prior to their injection (shooting) 
into the analytical system(Martínez-Lozano & Rus, 2010; Vuckovic, 2012). On the other hand, 
ultrafiltration uses molecular weight cut-off filters of 3000 Da or higher providing the best coverage for 
low-molecular weight compounds in global urine metabolome analysis (Pesek et al., 2009; Vuckovic, 
2012).  
In targeted analysis, however, where a limited group of metabolites are investigated, selective 
analytical extraction techniques, such as solid phase extraction (SPE) or liquid-liquid extraction (LLE) 
can be used for pre-concentration and clean-up purposes (Dunn et al., 2011; Fernández-Peralbo & Luque 
de Castro, 2012; Peng & Li, 2013; Urpi-Sarda et al., 2009). Phenolic conjugated metabolites and colonic 
microbial metabolites that are produced due to regular cocoa consumption were extracted from plasma 
and urine using simple and fast SPE procedures (Urpi-Sarda et al., 2009). Quantitative analysis of the 
extracted urine samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS) revealed 
the significant increase of phase II metabolites including glucuronide and sulfate conjugates of 
epicatechin, O-methyl-epicatechin, 5-(3′,4′-dihydroxyphenyl)-γ -valerolactone and 5-(3′-methoxy-4′-
hydroxyphenyl)-γ -valerolactone. The findings suggest the aptness of these compounds as urinary 
biomarkers of the consumption of flavanol rich food (Urpi-Sarda et al., 2009).  
Despite being an older technique relative to SPE, LLE is still capable of providing clean samples 
for metabolome analysis. For example, carboxylic acids urinary metabolic profiles generated using pre-
column derivatization reaction followed by reverse-phase liquid chromatography (RPLC)-Fourier 
transform ion cyclotron resonance mass spectrometry (FTICR-MS) were compared with and without the 
incorporation of a LLE clean-up step (Fig 2) (Peng & Li, 2013). It was shown that the additional pre-
concentration improved the sensitivity of quantification of organic acid metabolites. Moreover, water in 
urine, which reacts with the derivatizing reagent and thus reduces the reaction efficiency, was eliminated 
through the additional LLE process. Interference from highly abundant amino acids was also removed 
allowing the detection of other acids present in low concentrations. As a result, 2491 MS peaks were 
detected in urine samples after LLE in comparison to 874 peaks detected without extraction (Peng & Li, 
2013).  
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Fresh urine is characterized by the presence of human cells, bacteria and non-cellular 
components including urates and mucus filaments (Bernini et al., 2011; Sykes, 2007). Accordingly, prior 
to analysis, urine samples can be treated either through filtration, centrifugation or via the addition of a 
preservative (Sykes, 2007). It was shown that spinning of urine samples at 10,000 rpm for 10 min was 
less effective in conserving the metabolome composition in comparison to filtration through 0.22 µm 
syringe filter (Sykes, 2007). The addition of  sodium azide, a preservative, in a concentration of 10 mM 
provided better metabolic stability after a 4-week storage period at room temperature in comparison to 
lower concentrations (Sykes, 2007). Among all preparation methods, filtration showed superior ability 
to preserve the metabolic profile during storage which can be attributed to bacterial removal. However, 
the loss of larger metabolites through filtration should be taken into account (Sykes, 2007).  
C.  Sample Storage 
Following sample collection, immediate freezing is usually recommended in order to quench any 
rapid degradation activity such as oxidation of labile metabolites as well as various enzymatic reactions 
(Bernini et al., 2011; Fernández-Peralbo & Luque de Castro, 2012; Ryan et al., 2011; Sykes, 2007; van 
de Merbel, 2008). Sykes et al (Sykes, 2007) demonstrated significant changes in a considerable number 
of metabolites in both male and female urine samples after a 4-week storage period at 22 ºC using NMR 
combined with analysis of variance (ANOVA) and t-test statistical tools. Creatinine decreased 
significantly due to bacterial creatininase activity with the concomitant rise in creatine levels (Sykes, 
2007). This instability is concerning as normalization to creatinine, as discussed below, is the most 
widely employed method for the correction of urine volume variation (Ryan et al., 2011). Storing urine 
samples at 4 ºC for 4 weeks in the same study resulted in altered urine metabolic profile. However, that 
variation was less significant in comparison to samples stored at room temperature (Sykes, 2007). 
Similarly, metabolic changes were observed in urine following a week of storage at 4 ºC using NMR 
(Lauridsen et al., 2007). A decrease in hippurate concentration was observed with the simultaneous rise 
in its degradation products; benzoic acid and glycine. Long term sample storage at same conditions 
(above 1 week) caused further increase in acetate and decrease in histidine and citrate concentrations 
(Lauridsen et al., 2007). Likewise, another study confirmed the degradation of metabolites and the 
production of artifacts in urine samples stored at 4 ºC (Trivedi et al., 2012). 
On the contrary to the above discussed studies,  it was demonstrated that storing samples at 4 ºC 
for 24 hrs after collection and prior to storage at -80 ºC did not alter the metabolic profile compared to 
samples directly stored at -80 ºC (Dunn et al., 2008). Samples were analyzed using gas 
chromatography-Time of Flight (GC-ToF) MS and statistical analysis of the results was achieved using 
univariate statistical analysis as well as principle component analysis (PCA) (Dunn et al., 2008). 
Interestingly, another study supported the notion of fridge stability by indicating that urine sample 
storage at 0-4 ºC in a fridge or cooled autosampler for up to 48 hrs maintained the metabolic integrity of 
the samples (Gika, Theodoridis & Wilson, 2008b). Analysis was performed using both LC-quadrupole 
linear ion trap (LTQ) and ultra highperformance liquid chromatography (UPLC)-Quadrupole-Time of 
Flight (QToF) MS and results were analyzed using PCA (Gika, Theodoridis & Wilson, 2008b).  
Concerning the optimum freezing temperature for long term storage, Gika et al (Gika, 
Theodoridis & Wilson, 2008b) proved that the PCA score plots of urine samples stored at either -20 or -
80 ºC for a period of up to 6 months did not show any significant differences. This study, however, did 
not confirm whether or not the stored samples are identical to the original ones at the time of collection ( 
(Gika, Theodoridis & Wilson, 2008b). Likewise, Lauridsen and co-workers (Lauridsen et al., 2007) 
confirmed previous stability results by obtaining identical NMR patterns for urine samples stored for 26 
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weeks at either -25 ºC or -80 ºC. In addition, it was demonstrated that no benefits can be obtained by 
the addition of 15 mM sodium azide to samples intended to be stored at either temperatures for 26 weeks 
(Lauridsen et al., 2007). Another study confirmed the necessity of storing urine at -20 ºC or at even 
lower temperatures in order to maintain the integrity of the samples (Trivedi et al., 2012). Clearly, 
stability of metabolites is maintained at lower temperatures of storage; however, a conclusive agreement 
on urine metabolome behavior at higher storage temperatures (0-4 ºC) is lacking. The exact reason 
beyond these conflicting reports cannot be easily identified. Such variations can be attributed to many 
variables such as number of participants, time of urine collection, methods of sample preparation and 
methods of analysis.  
D. Freeze-Thaw stability 
It is recommended that freeze-thaw cycles are to be avoided as much as possible to prevent potential 
degradation; urine samples should be frozen in a pre-aliquot fashion following collection (Vuckovic, 
2012; Want et al., 2010). Urine samples which were frozen at -80 ºC and thawed twice a week for 4 
weeks showed reduced metabolic stability in comparison to non-thawed ones stored at the same 
temperature (Sykes, 2007). In contrast, Gika et al. demonstrated urine sample stability for up to 9 freeze-
thaw cycles (Gika, Theodoridis & Wilson, 2008b). It should be noted, however, that samples in the latter 
study were stored at -20 ºC and were allowed to thaw at room temperature for 3 h for 9 days (1 
cycle/day) (Gika, Theodoridis & Wilson, 2008b). The shorter study period (9 days versus 4 weeks) may 
explain the relative stability of urine samples despite the same number of freeze-thaw cycles. 
Interestingly, Trivedi et al. evaluated the stability of urine after 5 freeze-thaw cycles from -20 ºC over 5 
days and found that the urinary profiles can be maintained only up to 3 cycles (Trivedi et al., 2012). 
Again, due to the lack of comprehensive studies on freeze and thaw stability, this procedure should be 
avoided, or minimized as much as possible in urine metabolome analysis. 
III. MASS SPECTROMETRIC TECHNIQUES EMPLOYED IN URINE METABOLOMIC 
ANALYSIS  
Compared to other analytical techniques, MS has the advantages of high sensitivity, selectivity 
and chemical identification capabilities for unknown metabolites (Dunn, 2008; Dunn et al., 2011; Dunn 
& Ellis, 2005; Lei, Huhman & Sumner, 2011). When combined with chromatographic separation, it 
allows for the detection of thousands of compounds in a global manner as well as the quantification of 
metabolites in targeted analysis (Dunn et al., 2011; Dunn & Ellis, 2005). However, quantification 
necessitates the inclusion of internal standard (IS) to compensate for the variation of response factor due 
to sample matrix effects (Dunn et al., 2011). A wide variety of ionization sources are available, though 
electron impact (EI) and electrospray ionization (ESI) are the most commonly used ionization 
techniques in metabolomic analysis (Dunn et al., 2011). EI is the ionization of choice when GC is 
utilized, while ESI allows coupling of  LC or capillary electrophoresis (CE) to MS (Dunn et al., 2011; 
Lei, Huhman & Sumner, 2011). It is often required in the global approach to analyze the same sample in 
the positive and negative ion modes; such a protocol provides broader metabolome coverage through the 
detection of two metabolite sets that can substantially differ in chemical structures (Dettmer, Aronov & 
Hammock, 2007; Theodoridis, Gika & Wilson, 2011). ToF, QToF, FTICR-MS and orbitrap are high 
resolution mass analyzers that allow for the identification of co-eluting metabolites with the same 
nominal mass. Therefore, these are the analyzers of choice in untargeted metabolomic analysis (Guo et 
al., 2012; Mikami, Aoki & Kimura, 2012; Want et al., 2010). Triple quadrupoles (QqQ), however, are 
more suited for quantitative purposes in targeted analysis (Mikami, Aoki & Kimura, 2012; Want et al., 
2010). Although the use of neutral loss and precursor/product ion scans in urine metabolome analysis is 
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reported (Bicker et al. 2005; Lafaye et al., 2004; Wagner et al., 2006), multiple reaction monitoring 
(MRM) provides the highest sensitivity and a wider dynamic range (Lu, Bennett & Rabinowitz, 2008). 
A. Direct Injection (Infusion) Mass Spectrometry (DIMS) 
In this approach, the diluted urine sample is directly infused into ESI-equipped mass 
spectrometers without any prior chromatographic separation. Undiluted urine, however, is rarely used 
due to the high concentration of contained salts which are not normally removed via filtration. Injection 
can be done via a syringe or in an automated direct flow injection mode (DFI). In DFI, the sample 
passes through lines of the LC pumping systems without any chromatographic separation thus allowing 
for the fast and accurate introduction of various solutions from different LC vials placed in the 
autosampler (Dettmer, Aronov & Hammock, 2007; Dunn et al., 2008; Dunn et al., 2011). DIMS is a 
powerful tool for structural elucidation of hundreds of metabolites within a single run. Therefore, with 
its short analysis time and comparable prediction capabilities to LC-MS, it can be regarded as a “fit for 
purpose” approach in high throughput untargeted metabolomics (Kirwan et al., 2013).  However, despite 
its high detection power for all contained metabolites, this technique is limited by its inability to 
distinguish between isobaric molecules such as; stereoisomers (hexose sugars) or structural isomers 
(leucine and isoleucine), which possess the exact molecular weights (Dettmer, Aronov & Hammock, 
2007; Dunn et al., 2011; Dunn & Ellis, 2005). In addition, DIMS exhibits remarkably high ionization 
suppression (Dettmer, Aronov & Hammock, 2007; Dunn et al., 2011; Dunn & Ellis, 2005; Want et al., 
2010). A 60% ion suppression of internal standards spiked in rat urine was observed in comparison to 
standards spiked in saline solution despite the removal of salts from urine using online SPE extraction 
(Fig 3) (Dettmer, Aronov & Hammock, 2007). DIMS also can rapidly cause a deterioration of the 
performance of the instrument due to non-volatile residues (Dettmer, Aronov & Hammock, 2007). Due 
to such hurdles, its use is limited to rapid high-throughput screening purposes when a large number of 
samples are investigated for fingerprinting or putative identification (Mikami, Aoki & Kimura, 2012; 
Zhang et al., 2012a). Due to the anticipated increase in metabolomics studies, recent reports investigate 
possible means to overcome the technical challenges facing the widespread use of DIMS. For instance, 
non-volatile residues are required to be regularly removed through routinely scheduled maintenance of 
the ion source (Kirwan et al., 2013). In addition, Kirwan et al. have recently developed computational 
workflows that significantly decreased the analytical variation to the acceptable levels as per the Food 
and Drug Administration (FDA) guidelines for new biomarker discovery (Kirwan et al., 2013; Kirwan, 
2014). 
As in the case of other biological fluids, due to urine complexity, the use of DIMS usually 
involves the use of high resolution mass analyzers such as FTICR-MS or ToF (Dettmer, Aronov & 
Hammock, 2007; Dunn et al., 2011; Dunn & Ellis, 2005; Han et al., 2008; Hasegawa et al., 2007). 
FTICR-MS was used to detect differences in metabolic profiles of rat urine due to amiodarone induced 
phospholipidosis (Hasegawa et al., 2007). The PCA score plots confirmed that amiodarone treated-rat 
urine was different in biochemical composition than control urine. About 20% of the detected ions were 
altered by more than 1.5 fold due to amiodarone dosing. Furthermore, the identities of three altered 
metabolites due to amiodarone treatment were confirmed (Hasegawa et al., 2007). Similarly, analysis of 
urine samples collected from 55 cancer patients using DFI-MS coupled to LTQ analyzer was able to 
confirm that body lean and fat mass in cancer patients have distinct metabolic profiles (Stretch et al., 
2012). In conclusion, the widespread use of DIMS in urine metabolomics is currently being hampered 
by many technical and analytical challenges. However, with the continuously evolving research for 
improving its performance, an increase in the application of DIMS in urine metabolomics is anticipated 
in the near future.  
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B. Gas Chromatography- Mass Spectrometry (GC-MS) 
The use of GC-MS is inherently biased towards low molecular weight volatile compounds 
making it well-suited for metabolomic analysis (Dunn et al., 2011). Unfortunately, the majority of 
metabolites lack sufficient volatility and therefore, chemical derivatization is employed to enhance their 
volatility (Dunn et al., 2011). In general, oximation followed by trimethylsilylation with various 
reagents such as bis-(trimethylsilyl)–trifluoroacetamide (BSTFA) convert metabolites bearing diverse 
functional groups (-COOH, -NH2, -OH, -SH and others) into volatile products (Begley et al., 2009; 
Dunn et al., 2011; Fiehn et al., 2000; Halket et al., 2005; Villas-Bôas et al., 2011). However, this type of 
reactions consume longer times and produce lower stability products relative to the simpler alternative 
alkylation reactions with reagents as ethyl chloroformate (ECF)  (Fig 4) (Dunn et al., 2011; Villas-Bôas 
et al., 2011). 
GC-MS technique is generally used in urine metabolomic studies especially in the area of cancer 
biomarker discovery. A global metabolic profiling approach of urine using GC-ToF and UPLC-QToF 
identified 31 metabolites involved in bile acid, fatty acids, urea cycle and methionine metabolism as 
candidate diagnostic biomarkers in human hepatocellular carcinoma (HCC) (Chen et al., 2011b). 
Samples were collected from 177 participants (82 HCC patients, 24 benign liver tumor patients, 71 
healthy controls). For GC-ToF, samples were diluted 1:1 with water (final volume 600 µL) and spiked 
with L-2-chlorophenylalanine as internal standard. Derivatization was achieved using ECF to yield 
volatile derivatives that were analyzed following LLE extraction (Chen et al., 2011b). It is worth to note 
that these metabolites, with the exception of threonine and hypoxanthine, were totally different than 
those detected by an earlier study which employed GC-MS coupled to a lower resolution mass analyzer, 
Quadrupole (Q), to differentiate between HCC and healthy participants (Wu et al., 2009). In the latter 
work, samples from 20 patients were used to identify 18 metabolites as potential diagnostic markers for 
HCC (Wu et al., 2009). A relatively larger urine volume (1 mL) was spiked with the aforementioned 
internal standard, filtered and derivatized with BSTFA (Wu et al., 2009). With the exception of 3 
biomarkers, the differential expression of the detected metabolites was not justified nor their relevant 
metabolic pathways were illustrated (Wu et al., 2009). The significantly larger number of detected 
biomarkers in the first study (Chen et al., 2011b) can be attributed to its complementary use of two high 
resolution techniques. In addition, the larger sample size in the first study provided an additional benefit 
of enhanced statistical power.  
In another work, a computational method was employed to identify nine genome-wide altered 
metabolic pathways in breast cancer (Nam et al., 2009). One hundred and twenty eight candidate 
biomarkers were selected. These metabolites were identified in the urine of 100 participants using GC-
MS and fifteen of them were further quantified. The authors were able to recognize 4 metabolites 
(homovanillate, 4-hydroxyphenylacetate, 5-hydroxyindoleacetate and urea) to be statistically different 
between healthy and breast cancer patients (Nam et al., 2009). GC-Q-MS was also used in an untargeted 
and targeted approaches to differentiate between breast, cervical and ovarian cancer patients using urine 
samples (Woo et al., 2009). Statistical analysis of the result in the untargeted approach could only 
distinguish breast cancer from the other two types. When combined to LC-MS method, the targeted 
approach was able to confirm the previously reported two nucleoside; 5-hydroxymethyl-2-deoxyuridine 
and 8-hydroxy-2-deoxyguanosine, as diagnostic biomarkers for breast cancer and suggested three new 
potential biomarkers for ovarian cancer (Woo et al., 2009).  
To enhance the analytical performance of GC, two dimensional gas chromatography (GC×GC) 
coupled to MS was introduced. It is a relatively new technique that has been used in metabolomic 
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studies providing superior sensitivity and resolving power in comparison to conventional GC-MS 
(Almstetter, Oefner & Dettmer, 2012). A GC×GC-ToF method was able to target and quantify a 
complete set of biomarkers for six inherited metabolic disorders which was not achievable with a GC-Q-
MS method (Wojtowicz et al., 2010).  Recently, a GC×GC-ToF method was applied to an untargeted 
comprehensive evaluation of volatile metabolites in human urine (Rocha et al., 2012). Samples were 
extracted using solid phase micro extraction (SPME) prior to analysis. A total of 700 peaks were 
detected per sample, indicating the rich composition of urine for volatile compounds. Additionally, the 
volatile urine metabolome profiles obtained from smokers and non-smokers were also compared and 
differentiated. The investigation was possibly the most complete informative study covering the volatile 
metabolite component within the human urine (Rocha et al., 2012).  
In conclusion, GC is the oldest hyphenated technique that has been used in combination with MS 
for over 50 years and it has been often described as the gold standard in metabolomics (Dunn et al., 
2011; Dunn & Ellis, 2005). Despite the continuous introduction of new and advanced techniques, GC-
MS is still considered as a highly attractive tool in metabolomics. This can be attributed to the numerous 
well-established and commercially available metabolite libraries and retention indices which are not 
readily available in LC-MS methods (Ryan et al., 2011). However, the implementation of lengthy pre-
chromatographic derivatization and extraction steps to ensure analyte stability and volatility still 
constitute an unavoidable impediment to its wide applications (Dettmer, Aronov & Hammock, 2007; 
Lei, Huhman & Sumner 2011; Theodoridis, Gika & Wilson, 2011; Theodoridis et al., 2012). Such 
sample pre-treatment often introduces variability as well derivatization artifacts to the analyzed samples 
which complicate data interpretation (Dettmer, Aronov & Hammock, 2007; Johnson & Gonzalez, 2012; 
Lei, Huhman & Sumner 2011; Theodoridis et al., 2012; Villas-Bôas et al., 2011). Furthermore, it was 
reported that silylation can results in conversion reactions such as the conversion of arginine into 
ornithine (Halket et al., 2005). However, the inherent analytical advantages of GC-MS as high 
sensitivity, reproducibility, and resolution power outweigh its associated problems and endorse it as a 
cornerstone tool in the complete analysis of the urine metabolome (Johnson & Gonzalez, 2012; Scalbert 
et al., 2009; Theodoridis, Gika & Wilson, 2011; Theodoridis et al., 2012).  
C. Capillary Electrophoresis- Mass Spectrometry (CE-MS) 
In CE-MS, charged metabolites are separated based on their differential migration velocities in an 
electrically conductive liquid phase under the influence of an external electric current (Bayer, 2001; 
Dunn et al., 2011). CE-MS exhibits comparable or better separation efficiency than GC-MS and LC-MS 
in terms of shorter analysis times. However, CE-MS is less frequently used in urine metabolome 
analysis due to its lower sensitivity and its poor reproducibility in both peak area and migration time. 
Such inconsistencies are caused by the sorption of macromolecules in urine onto the capillary wall 
(Dunn et al., 2011; Lei, Huhman & Sumner 2011; Theodoridis, Gika & Wilson, 2011). Therefore, in 
comparison to GC-MS and LC-MS, the number of investigations employing CE-MS in urine 
metabolome analysis is limited, with more applications in fingerprinting rather than the quantitative 
targeted platform (Ramautar et al., 2011; Ramautar, Somsen & de Jong, 2009, 2013). For example, a 
CE-ToF method was developed for the profiling and the targeted analysis of free estrogens and their 
glucuronide and sulfate conjugates (Kuehnbaum & Britz-McKibbin, 2011). In spite of adequately 
resolving free and conjugated estrogens in alkaline buffer, the method could not detect endogenous 
estrogens present in sub-micromolar concentrations in human urine due to inadequate sensitivity. 
Moreover, the incorporation of an additional SPE step resulted in the removal of the conjugated forms 
from enriched premenopausal female urine extracts (Kuehnbaum & Britz-McKibbin, 2011).  
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CE-MS is more suited for the separation of cationic species over anionic compounds. For the 
latter group, modifications can be done to the capillary through coating with cationic surfactants (Yang, 
Regnier, & Adamec, 2008). However, cationic surfactants are subjected to alkaline hydrolysis causing 
the creation of voids within the separation phase and subsequent current drop (Soga et al., 2003). An 
alternative simpler approach is to modify the physical and chemical properties of anions through 
derivatization with a positively charged derivatizing agent. Profiling of carboxylic acid-containing 
metabolites in rat urine using CE-MS and CE-MS/MS was feasible through using N-butyl-4-
aminomethylpyridinum iodide (BAMP) and N-hexyl-4-aminomethyl-pyridinum iodide (HAMP) 
reagents (Fig 5)  (Yang, Regnier, & Adamec, 2008). After derivatization, positively charged compounds 
were produced and analyzed through normal CE mode. Analysis of rat urine revealed 59 candidate ions 
matching the characteristic pattern of carboxylic acids, out of which, only the identity of 32 was 
confirmed (Yang, Regnier, & Adamec, 2008).  
CE-MS was also applied for the analysis of polypeptides in urine. Polypeptides serve as an 
important biomarker group for renal diseases. A CE-ToF method was utilized in screening urine samples 
obtained from patients suffering from kidney disease and healthy individuals (Wittke et al., 2003). A 
healthy urine pattern consisting of 247 polypeptides was established and it was found to be distinctively 
different from that of the diseased patients. Twenty seven polypeptides, that were not present in the 
healthy patterns, were present in more than 50% of urine samples obtained from the patient population. 
In addition, thirteen of the normal polypeptides were absent in the urine of these patients (Wittke et al., 
2003).  
D. Liquid Chromatography- Mass Spectrometry (LC-MS) 
LC, coupled to different detection techniques, is the most widely employed platform in urine 
analysis. Combined with the qualitative and quantitative capabilities of MS, and due to the continuous 
improvements in its related technologies (i.e. UPLC, Hydrophilic interaction chromatography (HILIC)), 
LC-MS is ideally suitable for metabolomics studies, where it can be tailored for targeted or untargeted 
purposes (Ryan et al., 2011; Theodoridis, Gika & Wilson, 2011; Zhang et al., 2012a). In general, RP 
stationary phase is well suited for the separation of non-polar and polar metabolites in urine (Dettmer, 
Aronov & Hammock, 2007; Lei, Huhman & Sumner 2011). However, when highly polar low molecular 
weight metabolites are analyzed, they are usually eluted near or at the void volume with poor 
reproducibility (Dettmer, Aronov & Hammock, 2007; Pesek et al., 2008; Zhang et al., 2012c). 
Therefore, aqueous normal phase (ANP) is a convenient alternative for such compounds, where silica 
hydride-based high-pressure liquid chromatography (HPLC) stationary phases separate metabolites 
through a dual retention mechanism of hydrophilic and hydrophobic interactions (Pesek et al., 2008; 
Zhang et al., 2012c). RP and ANP in combination with QToF and QqQ-MS were utilized for the global 
metabolite mapping and discovery of potential biomarkers of bladder cancer (Putluri et al., 2011). By 
adopting non-targeted and targeted approaches, 25 metabolites were identified suggesting their aptitude 
for further investigation as diagnostic and prognostic biomarkers of bladder cancer (Putluri et al., 2011).  
HILIC is another suitable technology for the separation of ionic-polar metabolites (Buszewski & 
Noga, 2012; Chen et al., 2009; Ryan et al., 2011; Want et al., 2010). HILIC is a hybrid between normal 
phase (NP)-LC and RP-LC systems. Similar to NP-LC, polar stationary phases such as silica or 
derivatized silica (amino or cyano) are used allowing for the separation of polar metabolites that cannot 
be retained on RP-LC columns. Meanwhile, HILIC shares the use of water-containing polar organic 
mobile phases similar to RP-LC. Therefore, HILIC solves the problem of the limited solubility of polar 
metabolites that cannot be separated using NP-LC mobile phases (Buszewski & Noga, 2012). A 
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comparative evaluation of the metabolome profiles of rat urine using HILIC and RP columns utilizing 
UPLC-QToF system revealed that the two separation technologies provide complementary data leading 
to a better metabolome coverage (Gika, Theodoridis, & Wilson, 2008a). The use of C18 column (i.e. RP 
chromatography) produced data containing a larger number of observed peaks with enhanced resolution. 
On the other hand, sensitivity was enhanced with the HILIC column which could be attributed to the 
superior ionization desolvation process resulting from the higher organic composition of the mobile 
phase needed for the elution of the well-retained compounds (Gika, Theodoridis & Wilson, 2008a). In 
general terms, HILIC can explore different portions of the urine metabolome giving data on “MS 
friendly” zwitterion as well as highly polar metabolites such as taurine, betaine, creatine, creatinine and 
carnitine (Gika, Theodoridis & Wilson, 2008a; Lei, Huhman & Sumner 2011; Trivedi & Iles, 2014b; 
Trivedi et al., 2012; Zhang et al., 2012c). Both UPLC-RP and HILIC were employed to screen the urine 
metabolic profiles from liver cancer patients and healthy participants using QToF (Chen et al., 2009). As 
predictable, compared to RPLC-MS, HILIC-MS produced more sensitive response allowing for a better 
separation of the two groups. However, RPLC-MS was useful in separating compounds related to fatty 
acid oxidation as acylcarnitines. Out of the 21 identified potential biomarkers, the HILIC mode was able 
to detect 16 metabolites. In addition, it was able to retain and separate some of the hydrophobic 
acylcarnitines that were analyzed by RPLC due to the presence of quaternary ammonium group within 
their structures (Chen et al., 2009).  
In addition to column technologies, the introduction of UPLC has resulted in significant 
improvements in urine metabolome analysis (Dettmer, Aronov & Hammock, 2007; Wang et al., 2011). 
The performance of conventional HPLC to UPLC was compared using orthogonal acceleration-ToF 
(oaToF) in the profiling of urine obtained from three different mouse strains (Fig 6) (Wilson et al., 
2005). Using UPLC, method sensitivity was enhanced by 3-5 folds while providing 10 folds faster 
analyses. Sharper and distinct peaks were also obtained with substantial improvement in resolution 
which is reflected by the number of detected metabolites (13,000 in UPLC vs. 2,000 in HPLC) (Wilson 
et al., 2005). Similarly, the performance of a UPLC-oaToF-MS method developed for high throughput 
discrimination of five rodent strains according to age, gender, strain and diurnal variation (Plumb et al., 
2005) was compared to a previously developed HPLC-ToF method (Plumb et al., 2003). According to 
the authors, 3,900 marker ions were detected in a 1.5 min run time using UPLC-oaToF in comparison to 
merely 1,000 ions detected in the 10 min run of HPLC-QToF (Plumb et al., 2005; Plumb et al., 2003).  
IV. LC-MS QUANTITATIVE APPROACHES 
 
A. Stable Isotope Labeling (SIL) 
Following identification in the untargeted approach, candidate metabolites must be quantified in 
urine for the selection of potential biomarkers using various statistical tools. However, when ESI is used 
as the ionization source, ion suppression from co-eluting molecules and matrix interference is a major 
impediment in MS quantitative analysis (Gangl et al., 2001; Guo & Li, 2009; Ryan et al., 2011; Stokvis 
et al., 2004; Toyo’oka, 2012). Therefore, regardless of the used MS- based technique, quantification of 
metabolites in the targeted approach cannot be achieved through external standard (ES) calibration and 
the use of internal standards (IS) becomes inevitable (Dunn et al., 2011). Structural analogues, when 
used as IS, might elute at different times than the compounds of interest and would consequently 
experience different matrix effects leading to insufficient accuracy and precision (Guo, Ji & Li, 2007; 
Ryan et al., 2011; Stokvis et al., 2004). One strategy to overcome such hurdles is the use of an 
isotopically labeled internal standard (i.e. stable isotope labeling, SIL) (Guo & Li, 2009; Jacob et al., 
2002; Ryan et al., 2011; Toyo’oka, 2012). For example, the analytical performance of an HPLC-QqQ 
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for the determination of 1-hydroxypyrene (a biomarker of polycyclic aromatic hydrocarbon exposure) in 
urine using two calibration modes was evaluated (Pigini et al., 2006). Blank urine was spiked either with 
external reference standard of 1-hydroxypyrene or with 1-hydroxypyrene-d9 as an IS. The analytical 
performance of the methods regarding linearity, precision and accuracy did not significantly differ 
between the two calibration strategies. Such findings were confined to when the same urine was used for 
both calibrations, and therefore the matrix effect was unified. However, it was confirmed that external 
calibration cannot be used in routine biomarker analysis where, logically, urine samples from different 
subjects are investigated (Pigini et al., 2006).  
Although efficient in overcoming matrix effect, the use of SIL is well suited when a single 
(Jacob et al., 2002; Kuklenyik, Ashley & Calafat, 2002) or few compounds (Clarke et al., 2002; 
Weimann, Belling, & Poulsen 2002; Xu et al., 2005) are to be traced in urine. However, when large 
numbers of urinary metabolites are targeted, SIL approach is expensive and impractical due to the 
structural diversity of metabolites (Lei, Huhman & Sumner 2011; Toyo’oka, 2012). Furthermore, it has 
been shown that the addition of a large number of ISs may interfere with the detection of the 
investigated metabolites (Hodson et al., 2009).  
B. Differential Isotope Labeling (DIL) 
Another relatively new approach in metabolomics is the use of DIL where metabolites are 
targeted based on their common functional groups. An isotope labeled derivatizing reagent introduces an 
isotope tag to the investigated metabolite group within a urine sample. An isotopically-labeled analogue 
of the same reagent, commonly containing Deuterium (D) or 13C (i.e. heavy reagent), is used for the 
derivatization of a second comparable urine sample or standard solution. Finally, equal aliquots from 
light and heavy labeled solutions are mixed for relative or absolute quantification (Fig 7) (Guo & Li, 
2009; Toyo’oka, 2012). It is worth to note that there is a vast number of derivatizing reagents that 
proved to be useful in LC-MS analysis (Santa, 2013), however, Table 1 summarizes the most important 
reagents that were employed in metabolomic using urine as a biofluid. 
Guo K et al (Guo, Ji & Li., 2007) developed a 13C and deuterated-isotope dimethylation labeling 
reaction for the quantification of primary and secondary amine containing metabolites in urine through 
reductive amination. One concern regarding this reaction is that it resulted in minimum increase in 
hydrophobicity of polar metabolites through the formation of the dimethylated (primary amine) or 
monomethylated (secondary amine) derivatives. Consequently, the integrative use of HILIC and RP-LC 
was required for the analysis of “highly polar” and “less polar” metabolites, respectively, within each 
sample. In addition, despite providing a 4-Da mass difference with the deuterium dimethylated-labeled 
species, deuterated metabolites eluted at marginally different times than non-deuterated ones and the use 
of HILIC was fundamental to overcome such discrepancies (Guo, Ji & Li., 2007). The difference in the 
elution time is mainly due to the variance between C-H and C-D bond properties leading to differences 
in the interaction with the hydrophobic stationary phase. As a result, the isotope counterparts are 
subjected to different matrix and ion suppression effects (Turowski et al., 2003; Wade, 1999). To 
address such concern, the use of 13C labeling can theoretically eliminate elution issues related to the use 
deuterium for labeling. However, in case of 13C-methylation, light and heavy-labeled secondary amines 
exhibit only a mass difference of 1 Da, limiting the applicability of such labeling to merely high 
resolution MS instruments (Guo, Ji & Li., 2007). 
Due to the aforementioned drawbacks, another differential 12C-/13C-isotope dansylation labeling 
reaction was developed and resulted in significant improvements in the profiling of phenol and amine-
containing metabolites in urine (Fig 7) (Guo & Li, 2009; Zheng & Li, 2012). It was shown that the 
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introduction of a dimethyl amino naphthalene moiety resulted in; better retention of polar metabolites 
during LC analysis, enhancement of the ionization efficiency and improvement of signal intensity and 
signal-to-noise ratio. A dansylated library of 121 metabolites was constructed and used for the absolute 
quantification of 93 metabolites (Guo & Li, 2009).  
Recently, the organic acid urine sub-metabolome was analyzed through dimethylaminophenacyl 
differential labeling (Guo & Li, 2010; Peng & Li, 2013). The derivatized compounds resulted in 10-
1000 folds increase in signal intensity in comparison to their underivatized counterparts (Peng & Li, 
2013). Diverse DIL reactions were also developed to tag urinary metabolites bearing other chemical 
functional groups. For instance, thiols and disulfides were quantified in human urine through two 
sequential labeling reactions with two ferrocene-based maleimide reagents (Table 1) (Seiwert & Karst, 
2007). Furthermore, steroids containing a hydroxyl group were derivatized with deuterium 4-
(dimethylamino)-benzoic acid (d4-DMBA) (Table 1) (Dai et al., 2012).  Through D/H isotope DMBA 
tagging, twenty one steroidal hormones were relatively quantified in males, females and pregnant 
females urine using LC-LTQ-Orbitrap preceded by an SPE extraction step for the removal of abundant 
polar metabolites (Dai et al., 2012).  
In addition to overcoming ion suppression and matrix effects that hinder metabolite 
quantification, DIL adds other unique benefits in metabolome analysis. The additional hydrophobic tag 
allows polar metabolites to be retained on RP columns; therefore, their separation is enhanced. Higher 
organic phase is also needed for their elution, thus enhancing the ionization efficiency and sensitivity 
(Dunn et al., 2011; Eggink et al., 2010). Similarly, LC analysis of volatile compounds with limited 
stability, such as aldehydes, is challenging which can be addressed using DIL approach (Eggink et al., 
2010). The usefulness of 4-(2-((4-bromophenethyl) dimethylammonio)ethoxy)benzenaminium 
dibromide (4-APEBA) (Eggink et al., 2010) as a novel aldehyde derivatizing reagent was compared to 
the older reagent; 4-(2-(trimethylammonio)ethoxy) benzeneaminium dibromide (4-APC) (Table 1) 
(Eggink et al., 2008). The presence of the additional bromophenethyl group in the former reagent 
provided several benefits over the older generation. First, the increase in the molecular weight resulted 
in improvements in signal-to-noise ratio with 2 folds increase in the response of the derivatized 
products. Second, the new reagent reacted with carboxylic acid containing compounds as well, thus 
increasing its potentials as a suitable reagent for aldehydes and acids sub metabolome profiling. Third, 
the isotopic signature of 79Br/81Br produced distinct MS/MS fragmentation patterns facilitating 
identification (Eggink et al., 2010).  
V. LC-MS IN URINARY BIOMARKER DISCOVERY 
LC-MS has an indispensable role in exploring new diagnostic biomarkers (Roux et al., 2011; 
Zhang et al., 2012b), specifically, in the area of cancer as demonstrated by the previously discussed 
examples (Chen et al., 2009; Chen et al., 2011b; Woo et al., 2009). Due to the complexity of this 
disease, continuous studies are being conducted with the ultimate target of providing biomarkers that are 
non-invasively collected for early detection of different cancer types. In an attempt to quantify altered 
nucleosides in urogenital cancer, twelve nucleosides were analyzed using HPLC-QqQ-MS in the urine 
of healthy and urogenital cancer participants. Five nucleosides, namely; N-2-methylguanosine, 3-
methyluridine, 6-methyladenosine, inosine, and N,N-dimethylguanosine were found to be statistically 
different between the two groups (Struck et al., 2013). Despite this finding, it is difficult to ascertain that 
a specific nucleoside is a biomarker for a specific cancer type as the urinary levels of nucleosides are 
generally elevated in cancer patients due to the higher RNA turnover (Schram, 1998). In fact, some of 
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the identified nucleoside metabolites were also found to be differentially expressed between healthy and 
individuals having other types of cancer (Cho et al., 2009; Hsu et al., 2011; Jeng et al., 2009).  
As for renal cell carcinoma (RCC), a combination of UPLC-LTQ-MS and GC-MS methods 
established a signature urinary profile (Kim et al., 2011). Three biomarkers were differentially expressed 
in urine of RCC patients, where the concentrations of 4-hydroxybenzoate and gentisate decreased and 
that of quinolinate increased compared to control urine. However, the study was not able to confirm 
whether the three metabolites were specific only to RCC or to any kind of cancer in general. Further 
investigations involving global metabolome analyses and larger sample size were suggested before the 
use of the aforementioned metabolites as diagnostic biomarkers for RCC (Kim et al., 2011). 
In addition to cancer, biomarkers for other diseases have been investigated using LC-MS. A 
UPLC-QToF method was used for the non-targeted analysis of urine samples collected from patients 
with jaundice syndrome (Wang et al., 2012). Complete separation of patients from healthy individuals 
was achieved using 44 metabolites. Such metabolites were suggested to be further explored for the 
development of a clinically useful diagnostic tool (Wang et al., 2012).  
Another example is children who undergo cardiopulmonary bypass surgery (CPB). They are 
prone to the complication of acute renal injury (AKI) with a mortality rate over 50% (Beger et al., 2008; 
Williams et al., 2002). A UPLC-ToF method was developed for profiling urine samples obtained from 
40 children before and after CPB surgery (Beger et al., 2008). Patients developing AKI were well 
separated from the other group using PCA score plots. One potential biomarker suggested by PCA was 
further identified by MS/MS as homovanillic acid sulfate (HVA-SO4). Only 4 h following surgery, the 
concentration of HVA-SO4 was doubled in patients who developed AKI while slightly increased in 
patients without AKI. Therefore, HVA can serve as a potential biomarker allowing for early detection of 
AKI in this vulnerable population.  
Urinary metabolomics can also be useful in understanding complex psychological disorders such 
as depression (Zheng et al., 2010). A UPLC-QqQ method was used in the metabolic profiling of urine 
obtained from 16 healthy and chronic unpredictable mild stress model rats. Using PCA, complete 
separation between the two groups was observed in the positive and negative ion modes. In addition, six 
potential biomarkers related to energy metabolism, amino acid metabolism and gut microflora were 
identified (Zheng et al., 2010). Such detections highlight the potential of MS-based metabolomics for 
the future discovery of new urinary biomarkers suitable for the clinical diagnosis of complex 
psychological and neurological disorders. 
VI. INTEGRATIVE USE OF MS-BASED PLATFORMS FOR HOLISTIC URINE 
METABOLOME ANALYSIS 
The comprehensive analysis of metabolites within urine is, unfortunately, a technical challenge 
due to their diversity in physiochemical properties, concentrations, stabilities and excretion patterns. 
Mass spectrometric platforms such as LC-MS, GC-MS, DIMS, and CE-MS have become indispensable 
tools in system biology analysis due to their inherent sensitivity, specificity and quantitative capabilities. 
However, each of the aforementioned techniques has its own advantages and limitations concerning 
sensitivity, separation efficiency and cost. Therefore, the best strategy for holistic metabolome 
visualization is, logically, through the application of complementary analytical techniques (Dunn, 2008; 
Dunn et al., 2011; Dunn & Ellis, 2005; Kumar et al., 2012; Lei, Huhman & Sumner 2011; Woo et al., 
2009). For example, in an attempt to discover urinary biomarkers for hepatotoxicity, rats were orally 
dosed with carbon tetrachloride, acetaminophen and methotrexate (Kumar et al., 2012). Global profiling 
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of urine using UPLC-QToF followed by partial least square discriminate analysis revealed altered 
urinary patterns and the score plots of healthy and treated rats were separately clustered. Some 
metabolites belonging to three different metabolic pathways were selected as candidate hepatotoxicity 
biomarkers and these were classified into; steroids, bile acids and amino acids (Kumar et al., 2012). 
Urinary steroids were quantified using a previously published GC-MS method (Moon et al., 2009). It 
was found that urinary concentrations of 11β-OH-androsterone, epiandrosterone and estrone decreased, 
and that of 11-dehydrocorticosterone increased significantly following hepatotoxicity. As for bile acids 
and oxysterols, only cholic acid and lithocholic acid were differentially overexpressed in the urine of 
treated groups analyzed by another GC-MS method (Kumar et al., 2011). Finally, 25 amino acids that 
were differentially expressed in urine of the three treated groups were quantified using a CE-MS (Shama 
et al., 2008) and six compounds were selected as hepatotoxicity biomarkers.  
Six different platforms were also employed in order to widen the systematic characterization of 
the human urinary metabolome (Bouatra et al., 2013). This holistic approach led to the identification of 
445 and quantification of 378 unique metabolites. Four different GC-MS methods were applied to target 
bile acids, volatile compounds, organic acids and polar metabolites. In total, all methods led to the 
identification of 179 and quantification of 85 metabolites. A combined DFI-MS/MS and LC-MS/MS 
method led to the identification and quantification of 127 metabolites. Furthermore, quantitative results 
of 40 metals or trace elements were achieved by inductively coupled plasma (ICP)-MS.  
VII. MS DATA MINING AND STANDARDIZATION IN URINE METABOLOME 
ANALYSIS 
Enormous amounts of complex data are generated following the untargeted MS analysis of the 
urine samples, and in its current format, these data cannot be manually analyzed (Monteiro et al., 2013). 
Therefore, the first critical step in data mining is to correct all variations caused by the experimental 
variables. Data handling (including; peak normalization, peak alignment, baseline correction and peak 
deconvolution) is usually achievable through the use of commercially available software (Monteiro et 
al., 2013; Zhou et al., 2014).  Subsequently, multivariate statistical techniques (supervised and 
unsupervised) are performed to allow for the recognition of patterns between samples (i.e. between 
healthy and diseased patient’s urine) (Monteiro et al., 2013). As a final step, differentially expressed 
metabolites must be identified through the available databases before a targeted approach can be adopted 
(Dunn et al., 2011; Monteiro et al., 2013). Data analysis and interpretation is a fundamental step in 
metabolomic studies that may lead to erroneous results. However, this side of data handling is mainly 
involved with software manipulation rather than urine itself. Therefore, the reader is advised to refer to 
the literature for more comprehensive understanding of this topic (Katajamaa & Orešič, 2007; Monteiro 
et al., 2013; Scalbert et al., 2009).   
However,one concerning variable in data pre-processing that lies within the scope of this work is 
the variation in urine volume. . In fact, in addition to the complexity of urine metabolome composition, 
fluctuation in urine volume represents another analytical challenge as it results in erratic dilutions in 
metabolite concentrations. Urine volume varies from 600 to 2500 mL/day depending on the individual’s 
hydration status, which in turn is affected by fluid intake, humidity, temperature and physical activity 
(Hee, 1993; Ryan et al., 2011). Therefore, regardless of the analytical platform, mathematical 
manipulations of the analytical raw data must be done to normalize concentrations of metabolites to 
other urine properties with lower extend of variation than urine volume. Among the most common 
normalization strategies are the creatinine concentration, specific gravity and osmolality (Hee, 1993; 
Ryan et al., 2011).  
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In the absence of kidney diseases, creatinine is excreted in measurable and relatively constant 
amounts by glomerular filtration into the urine (Boeniger, Lowry & Rosenberg, 1993; Hee, 1993; Viau, 
Lafontaine & Payan, 2004; Warrack et al., 2009). In general, it is accepted that creatinine has minimal 
metabolic or excretory variances among healthy individuals (Adamko et al., 2007; Ryan et al., 2011). In 
other words, the amount of creatinine excreted per day is constant and approximately at a rate of 1 g per 
20 Kg of muscle mass ( Viau, Lafontaine & Payan, 2004). Creatinine’s rate of elimination is 
independent of urine flow and therefore, its concentration is inversely proportional to urine volume  
(Boeniger, Lowry & Rosenberg, 1993). Therefore, creatinine is accepted to behave as the best internal 
standard for correcting urine volume variations as the ratio of creatinine to the analyte of interest is 
maintained in urine (Adamko et al., 2007; Ryan et al., 2011). Despite being the most employed 
normalization technique, the suitability of creatinine, however, has always been debated due to the 
presence of various uncontrollable factors influencing its concentration such as age, gender, physical 
activity, time of the day and food intake (Boeniger, Lowry & Rosenberg, 1993; Ryan et al., 2011). 
Maintaining proper hydration and normal meat intake during sample collection can contribute to 
minimizing this variation ( Boeniger, Lowry & Rosenberg, 1993).  
Normalization to specific gravity is an alternative methodology that uses the mathematical 
equation developed by Levine and Fahy (Levine & Fahy, 1945) to correct the measured specific gravity 
of fresh urine to a mean specific gravity reference value, usually of 1.02  (Chadha, Garg & Alon, 2001; 
Cone et al., 2009; Heavner et al., 2006; Hee, 1993). However, like creatinine normalization, this method 
has several limitations. For instance, urine density is affected by the total mass of the solutes, which in 
turn is affected by their number and molecular weight. Therefore, the specific gravity method is not 
applicable in cases such as diabetes mellitus where high glucose concentration is excreted in urine as 
well as kidney patients with urine containing high protein content (Chadha, Garg & Alon, 2001; Miller 
et al., 2004). Furthermore, the mean specific gravity of normal urine is not constant and it has a range of 
1.016 to 1.024 (Heavner et al., 2006). Finally, urine density is affected by fluctuating temperature as 
well as the hydration state of the patient (Chadha, Garg & Alon, 2001; Miller et al., 2004). 
Similar to specific gravity, osmolality measures the total solute concentration in urine and it is 
determined by the depression in the solution’s freezing point or vapor pressure (Chadha, Garg & Alon, 
2001). In contrast to creatinine and specific gravity, osmolality is not affected by diurnal rhyme, diet, 
activity, age, gender, stress or mass, charge or size of particles (Chadha, Garg & Alon, 2001; Warrack et 
al., 2009). In fact, the determination of urine osmolality gives the most specific reflection of its 
metabolite concentration, however, this technique is not readily accessible in all laboratories (Chadha, 
Garg & Alon, 2001). Consequently, measuring specific gravity is usually implemented as it can be 
converted mathematically into an approximate corresponding osmolality value (Chadha, Garg & Alon, 
2001). 
A new normalization approach for amine and phenol containing metabolites using chemical 
labeling reaction was recently reported (Wu & Li, 2012). Urine samples were derivatized with dansyl 
chloride and analyzed by a very fast LC-UV method. The total concentration of all co-eluted labeled 
metabolites in each urine sample was calculated. The same sample was then analyzed by an LC-FTICR-
MS method and each selected metabolite was quantified using heavy and light dansyl chloride labeling 
and then normalized to the total concentration (Wu & Li, 2012). Although that the superiority of such 
normalization approach was clearly demonstrated over the creatinine and the osmolality approaches, the 
dansyl chloride method, however, requires the tedious steps of derivatization and running an additional 
LC-UV for the calculation of total labeled metabolite concentrations. In addition, it confines the 
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quantification to these metabolites bearing only primary or secondary amine and phenolic functional 
groups that can react with the designated reagent.  
Another new global normalization approach was developed using a customized software based 
on MS total useful signal “MSTUS” (Warrack et al., 2009). Untargeted urine analysis was first achieved 
using LC-LTQ-FTICR-MS. Subsequently, all signals present in the spectra of all samples were summed 
and used for the generation of MSTUS normalization factor. This strategy has the advantage of 
eliminating the interferences from xenobiotics and artifacts (Warrack et al., 2009).  
It is clear that despite the availability of different approaches for normalization, each has its own 
unavoidable limitations. For that reason, the application of two normalization strategies would definitely 
minimize the errors induced by either strategy and hence, confirm the changes detected within a urine 
metabolomic profile. 
VIII. CONCLUDING REMARKS 
Metabolomics research has intensified over the past decade as metabolites are the final output for 
biochemical activities within cells, providing an attractive platform for biomarker discovery.  Therefore, 
intense research has been conducted to link a disease state to a specific set of metabolites that can be 
used for diagnosis (Beger et al., 2008; Kim et al., 2011; Wang et al., 2012; Woo et al., 2009) or for 
monitoring disease progression (Pasikanti et al., 2010; Sreekumar et al., 2009) or response to therapy 
(Hasegawa et al., 2007; Kumar et al., 2010; Van Doorn et al., 2007). While any biological fluid can be 
used for the identification of clinically-significant biomarkers, urine is an ideal option as it can be 
collected non-invasively with no discomfort to patients.  Urine in particularly is an excellent choice for 
patients who cannot easily provide blood samples, such as children. However, little research has been 
performed regarding the stability of metabolites within urine after collection.  Most concerning is the 
conflicting reports regarding such stability (Dunn et al., 2008; Gika, Theodoridis, & Wilson, 2008a; 
Lauridsen et al., 2007; Sykes, 2007). It is, therefore, advisable that urine samples are aliquoted upon 
collection and stored at -80° C till the time of analysis.  
While many analytical tools can be used for the identification and quantification of urine 
metabolites, mass spectrometry, especially when linked to a suitable separation technique, can serve as 
an ideal platform for metabolomics research (Armitage & Barbas, 2014; Dunn et al., 2013; Trivedi & 
Iles, 2014a; Zhang et al., 2012a). MS offers the preferred sensitivity, high throughput capability and the 
desired quantitative outputs, absolute or relative. However, due to the versatile nature of metabolites, 
none of the currently available MS techniques can provide a single comprehensive characterization of 
any biofluid’s constituents, including the urine. Indeed, reports providing highly informative metabolic 
pictures usually involve the integrative implementation of two or more MS-based platforms (Bouatra et 
al., 2013; Chen et al., 2011b; Kim et al., 2011). 
Current MS-based research focuses on either developing identification/quantification methods 
for a subset of the metabolome based on the chemical structure (Guo & Li, 2009, 2010; Rijk et al., 2009; 
Struck et al., 2013) or the identification of a set of diagnostic biomarkers linked to a specific 
physiological condition such as cancer (Nam et al., 2009; Struck et al., 2013). Unlike genes or proteins, 
the key challenge for metabolites is their diverse chemical structure.  Recently, a subset of the urine 
metabolome was linked to asthma and COPD lung diseases using NMR (Saude et al., 2009; Saude et al., 
2011).  The next step is to quantify the target metabolites using MS platforms.  Due to the structural 
diversity of the identified metabolites, multiple MS-based methods (some of which require 
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derivatization) should be employed to obtain reliable quantitative data. Such a task is an example of one 
of the key challenges in MS-based metabolomics research.  
 
Another concern is the actual identification of the observed ions within an MS run. Many 
investigations simply report the number of identified peaks (sometime in the thousands range) without 
actually identifying the molecular structures of these peaks (Peng & Li, 2013; Rocha et al., 2012; 
Wilson et al., 2005).  Even when differentially-expressed ions are identified in terms of structure, the 
underlying biochemical pathways that led to their relative increase/decrease are rarely rationalized. Such 
challenge is maximized with the fact that MS methods are designed to target a subset of the metabolome 
while the biochemical pathway that is linked to a specific physiological state is most likely complex. 
The current state of MS-based metabolomics probably resembles the infancy state in which MS-based 
proteomics existed twenty years ago.  
In summary, it is clearly evident that MS metabolomics including urine-based is still at its 
infancy. More efforts are needed before validated sets of urinary biomarker metabolites can be routinely 
analyzed in clinical laboratories for the diagnosis and prognosis of complex diseases. However, the 
continuous development and merging of new and advanced high throughput hyphenated MS-based 
analytical techniques with strong bioinformatics tools will eventually allow for better interpretation of 
the metabolic data and wider understanding of the biochemical process occurring in the body. 
Assertively, the generated data must be shared in a way to permit use and re-use, however, a limited 
number of research groups freely provide their data to the scientific community. In 2005, the 
Metabolomics Standards Initiative (MSI) was launched with the goal of developing and communicating 
standards for the metabolomic community. The main aim within MSI group is to generate a broad 
community consensus around the proposed metabolomics standards so that the data can be available to 
others for evaluation or to support new research initiatives  (Dunn et al., 2011; Fiehn et al., 2007). 
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TABLE 1. Derivatizing reagents employed in urinary metabolites determination 
Reagent Functional group Chemical Reaction Application 
Dansyl chloride 
Primary, 
Secondary 
Amines 
Phenols 
S OO
Cl
N
CH3 CH3
+
N
RR
S OO
N
CH3 CH3
NH
R R
 
S OO
Cl
N
CH3 CH3
+ R
OH
R
O
S OO
N
CH3 CH3  
Profiling of amines and phenols submetabolome 
(Guo & Li, 2009) 
15 endogenous estrogens (Xu et al., 2005) 
5-Diethylamino-naphthalene-1-
sulfonyl Chloride (DensCl) 
Primary, 
Secondary 
Amines 
Phenols 
S OO
Cl
N CH3CH3
+
N
RR
S OO
NCH3 CH3
NH
R R
 
Profiling of amines and phenols submetabolome 
(Zhou, Guo & Li, 2013) 
Formaldehyde 
Primary and 
Secondary 
Amines 
R NH2 H
H
O
+ R N
CH3
CH3
NaBH3CN
 
Profiling of amine submetabolome (Guo, Ji & 
Li, 2007) 
4-(dimethylamino)-benzoic acid Alcohols  
OH
N
CH3
CH3
O
R OH
+ O
N
CH3
CH3
O
R
 
Hydroxyl containing steroidal hormones (Dai et 
al., 2012) 
Picolinic acid Alcohols 
N
OH
O
R OH
+
N
O
O
R
 
tetrahydrocortisol, allotetrahydrocortisol and 
tetrahydrocortisone (Yamashita et al., 2008) 
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2,4-dinitrophenylhydrazine 
(DNPH) 
Aldehydes 
OO
NH
NH2
NO2O2N
+
NO2
N
N
O2N
 
 
Malondialdehyde (Chen et al., 2011a) 
Succinic semialdehyde (Struys et al., 2005) 
Selected aldehyde (Baños & Silva, 2010) 
  
NH
NH2
NO2O2N
+R H
O
NH
N
NO2O2N
R
 
 
4-(2-(trimethylammonio) 
ethoxy)benzeneaminium 
dibromide 
(4-APC) 
Aldehydes 
NH3
+
O
N
+
CH3
CH3
CH3
Br
- Br
-
+ R H
O
NH
O
N
+
CH3
CH3
CH3
R
Br
- Br
-
 
Selected spiked aldehyde (Eggink et al., 2008) 
4-(2-((4- 
bromophenethyl)dimethylammon
io)ethoxy)benzenaminium 
dibromide 
(4-APEBA) 
Aldehydes 
and Carboxylic 
Acids 
NH3
+
O
N
+
CH3CH3
Br
Br
- Br
-
+ R H
O
NH
O
N
+
CH3CH3
R
Br  
 
R OH
O
NH3
+
O
N
+
CH3CH3
Br
Br
-
Br
-
EDC
NH
O
N
+
CH3CH3
R
O
Br
Br
-
 
Few spiked aldehyde (Eggink et al., 2010) 
Prostaglandins and NSAID (Kretschmer et al., 
2011) 
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p-Dimethylaminophenacyl 
bromide 
(DmPA) 
Carboxylic Acids 
N
O
Br
+
O
OH
R
OO
R
N
O
 
 
Profiling of carboxylic acid submetabolome 
(Peng & Li, 2013) 
heptadecafluoroundecylamine Carboxylic Acids NH2 C8F17+R
OH
O
R
O
NH C8F17
 
3 Sialic acids (Hayama et al., 2010) 
p-toluenesulfonhydrazone 
 
Ketones 
CH3
S
NH
NH2
O
O R
R
O
+
R
R
CH3
S
NH
N
O
O
 
Endogenous 2- and 4-hydroxyestrones (Xu, et 
al., 2002) 
N-(2-ferroceneethyl)maleimide 
ferrocenecarboxylic acid-(2-
maleimidoyl)ethylamide 
 
Thiols 
And 
Disulphides 
NH N
O
O
O
Fe
R SH+ NH N
O
O
O
S
R
Fe
 
cysteine, N-acetylcysteine, homocysteine, 
cysteinylglycine, and glutathione (Seiwert & 
Karst, 2007) 
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FIGURE 1. Strategies in metabolomic analysis for biomarker discovery. 
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FIGURE 2. Base-peak chromatogram of the urinary profiles before and after the incorporation of LLE 
for the determination of carboxylic acid sub metabolome using pre-column derivatization followed by 
RPLC-FTICR-MS, adopted from ref (Peng & Li, 2013), reprinted with permission. 
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FIGURE 3. Online SPE extraction of (A) 10 μL saline solution and (B) 10 μL rat urine spiked with 
internal standards coupled to direct infusion analysis using ESI in positive mode and TOF-MS detection 
(LCT, Micromass). Internal standards used: 1. Indole-3-acetic acid-d2, 2. 11-aminoundecanoic acid, 3. 
Melatonin-d4, ref (Dettmer, Aronov & Hammock, 2007), with permission. 
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FIGURE 4. General scheme of the trimethylsilylation (BSTFA) and alkylation (ECF) reactions in GC-
MS. 
R OH
O
R OH
R NH2
Cl O
O
CH3
R O
O
CH3
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R O CH3
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CH3
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N Si
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FIGURE 5. Reaction scheme for profiling of carboxylic acid-containing metabolites using N-butyl-4-
aminomethylpyridinum iodide (BAMP) and N-hexyl-4-aminomethyl-pyridinum iodide (HAMP) 
reagents in rat urine. 
R OH
O
N
+
NH2
R
+ N+
NH
R
O
R
EDC
R = C4H9, BAMP
    = C6H13, HAMP  
  
This is the peer reviewed version of: Khamis, M. M., Adamko, D. J. and El-Aneed, A. (2015), Mass Spec Rev., 
published in final form at https://doi.org/10.1002/mas.21455. 
 
28 
University of Saskatchewan Author Manuscript, available April 16, 2017.  
 
FIGURE 6.  Chromatographic separation of white female AM mouse urine using (A) HPLC, (B) UPLC 
and Extracted ion chromatogram m/z = 401 of white female AM mouse urine sample using either (C) 
HPLC, (D) UPLC, ref (Wilson et al., 2005), with permission 
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FIGURE 7. Schematic representation of light and heavy labeling for absolute and relative quantification 
of urinary metabolites in LC-MS based platform. Chromatogram adopted from ref (Guo & Li, 2009) 
with permission. 
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